New study tracks psoriatic arthritis treatment success across therapy lines
NCT ID NCT07417995
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study follows 400 adults with psoriatic arthritis who are starting a new biologic or targeted synthetic drug as part of their routine care. Researchers want to see if treatment response differs based on how many prior advanced therapies a person has tried, and whether blood tests can predict effectiveness. Participants will provide routine checkup data, symptom questionnaires, and blood samples before treatment and at 12 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 400 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults with a confirmed diagnosis of PsA, meeting CASPAR classification criteria, who are initiating a new advanced therapy (b/tsDMARD) as part of routine NHS care.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥18 years * Clinical diagnosis of PsA meeting CASPAR criteria * Starting a new b/tsDMARD, irrespective of line of therapy Exclusion Criteria: * Switching b/tsDMARD therapy for psoriasis or spondyloarthritis alone, without active psoriatic arthritis. * Previous treatment with the same b/tsDMARD being started at baseline. * Inability or unwillingness to provide informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Psoriasis arthritis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Royal United Hospitals Bath NHS Foundation Trust
Bath, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Job-Focused rehab program keep arthritis patients employed?
- Can an oral drug calm psoriatic arthritis? phase 3 trial puts deucravacitinib to the test
- Do rheumatic diseases quietly damage the Eye's oil glands?
- Can a questionnaire capture the real burden of psoriatic arthritis?
- Can a new pill calm psoriatic arthritis joint pain?
- A personal nurse and a plan: could this ease the daily burden of arthritis?